Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3375856 | 0.85 | MEN1 (0.33) | KMT2AMEN1RAD52SMN1; SMN2 | |
| SCHEMBL3375213 | 0.84 | ALOX15 (0.35) | KMT2AMEN1KDM4EALDH1A1ADRB2 | |
| SCHEMBL3373895 | 0.82 | ALDH1A1 (0.33) | KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL3373632 | 0.80 | ALDH1A1 (0.33) | KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3375013 | 0.80 | ALDH1A1 (0.33) | KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2360067 | 0.77 | HIF1A (0.39) | KMT2AMEN1SMN1; SMN2ALDH1A1ADRB2 | |
| SCHEMBL14556270 | 0.77 | HIF1A (0.39) | KMT2AMEN1SMN1; SMN2ALDH1A1ADRB2 | |
| SCHEMBL2160162 | 0.77 | HIF1A (0.39) | KMT2AMEN1SMN1; SMN2ALDH1A1ADRB2 | |
| SCHEMBL3434243 | 0.69 | ADRB2 (0.34) | KMT2AMEN1KDM4EALDH1A1ADRB2 | |
| SCHEMBL3375209 | 0.69 | ADRB2 (0.34) | KMT2AMEN1KDM4EALDH1A1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | claimed |
| EP-2340021-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | claimed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | claimed |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | DING QINGJIE | 2010-03-25 | — | — | US | claimed |
| EP-2534132-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2340021-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | disclosed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | disclosed |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | DING QINGJIE | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | KMT2A 703/4885TLR8 4148/4885TLR7 1789/4885 |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | KMT2A 703/4885TLR8 4148/4885TLR7 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.